Cristina Panaroni1,2, Andrew J Yee1,2, Noopur S Raje3,4. 1. Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Professional Office Building 216, 55 Fruit Street, Boston, MA, 02114, USA. 2. Harvard Medical School, Boston, MA, 02115, USA. 3. Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Professional Office Building 216, 55 Fruit Street, Boston, MA, 02114, USA. NRAJE@mgh.harvard.edu. 4. Harvard Medical School, Boston, MA, 02115, USA. NRAJE@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Bone disease is a defining characteristic of multiple myeloma (MM) and the major cause of morbidity. It manifests as lytic lesions or osteopenia and is often associated with severe pain, pathological fracture, spinal cord compression, vertebral collapse, and hypercalcemia. Here, we have reviewed recent data on understanding its biology and treatment. RECENT FINDINGS: The imbalance between bone regeneration and bone resorption underlies the pathogenesis of osteolytic bone disease. Increased osteoclast proliferation and activity accompanied by inhibition of bone-forming osteoblasts leads to progressive bone loss and lytic lesions. Although tremendous progress has been made, MM remains an incurable disease. Novel agents targeting bone disease are under investigation with the goal of not only preventing bone loss and improving bone quality but also harnessing MM tumor growth. Current data illustrate that the interactions between MM cells and the tumor-bone microenvironment contribute to the bone disease and continued MM progression. A better understanding of this microenvironment is critical for novel therapeutic treatments of both MM and associated bone disease.
PURPOSE OF REVIEW: Bone disease is a defining characteristic of multiple myeloma (MM) and the major cause of morbidity. It manifests as lytic lesions or osteopenia and is often associated with severe pain, pathological fracture, spinal cord compression, vertebral collapse, and hypercalcemia. Here, we have reviewed recent data on understanding its biology and treatment. RECENT FINDINGS: The imbalance between bone regeneration and bone resorption underlies the pathogenesis of osteolytic bone disease. Increased osteoclast proliferation and activity accompanied by inhibition of bone-forming osteoblasts leads to progressive bone loss and lytic lesions. Although tremendous progress has been made, MM remains an incurable disease. Novel agents targeting bone disease are under investigation with the goal of not only preventing bone loss and improving bone quality but also harnessing MM tumor growth. Current data illustrate that the interactions between MM cells and the tumor-bone microenvironment contribute to the bone disease and continued MM progression. A better understanding of this microenvironment is critical for novel therapeutic treatments of both MM and associated bone disease.
Entities:
Keywords:
Bisphosphonates; Bone marrow stromal cells; Multiple myeloma; Osteolytic bone disease; Tumor microenvironment
Authors: P I Croucher; C M Shipman; J Lippitt; M Perry; K Asosingh; A Hijzen; A C Brabbs; E J van Beek; I Holen; T M Skerry; C R Dunstan; G R Russell; B Van Camp; K Vanderkerken Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: Gareth J Morgan; Faith E Davies; Walter M Gregory; Alex J Szubert; Sue E Bell; Mark T Drayson; Roger G Owen; A John Ashcroft; Graham H Jackson; J Anthony Child Journal: Blood Date: 2012-04-12 Impact factor: 22.113
Authors: Gareth J Morgan; J Anthony Child; Walter M Gregory; Alex J Szubert; Kim Cocks; Sue E Bell; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona M Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; Ping Wu; Faith E Davies Journal: Lancet Oncol Date: 2011-07-21 Impact factor: 41.316
Authors: N Raje; S Vadhan-Raj; W Willenbacher; E Terpos; V Hungria; A Spencer; Y Alexeeva; T Facon; A K Stewart; A Feng; A Braun; A Balakumaran; G D Roodman Journal: Blood Cancer J Date: 2016-01-08 Impact factor: 11.037
Authors: Estefania Labanca; Elba S Vazquez; Paul G Corn; Justin M Roberts; Fen Wang; Christopher J Logothetis; Nora M Navone Journal: Endocr Relat Cancer Date: 2020-07 Impact factor: 5.678
Authors: Antonio Garcia-Gomez; Tianlu Li; Carlos de la Calle-Fabregat; Javier Rodríguez-Ubreva; Laura Ciudad; Francesc Català-Moll; Gerard Godoy-Tena; Montserrat Martín-Sánchez; Laura San-Segundo; Sandra Muntión; Xabier Morales; Carlos Ortiz-de-Solórzano; Julen Oyarzabal; Edurne San José-Enériz; Manel Esteller; Xabier Agirre; Felipe Prosper; Mercedes Garayoa; Esteban Ballestar Journal: Nat Commun Date: 2021-01-18 Impact factor: 14.919
Authors: Renza Spelat; Federico Ferro; Paolo Contessotto; Nicholas J Warren; Grazia Marsico; Steven P Armes; Abhay Pandit Journal: Mater Today Bio Date: 2020-01-07